RYTM logo

RYTM Rhythm Pharmaceuticals, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$112.36
-4.44 (-3.80%)

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies i…

Market Cap: $7.79Bwww.rhythmtx.com

Price

No data yet.

Social Signal Score

54
5d
—
30d
53
14 mentions
—
60d
54
17 mentions
—
90d
54
19 mentions
—
news: 12 · rss: 6 · marketaux: 1

Analyst Ratings

22 analysts
Buyconsensus
Strong Buy 0Buy 22Hold 0Sell 0Strong Sell 0
Avg price target$146.38+30.3%
Low $120Median $154.5High $160
Current Consensus

Revenue

$92.13M
$0.00$30.71M$61.42M$92.13M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-3.17
$-3.35–$-2.90
12 analysts
FY2026
$-5.05
$-8.18–$-2.35
12 analysts
FY2027
$-1.10
$-2.72–$-0.46
11 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
David Meeker
Sector
Healthcare
Industry
Biotechnology
Employees
414
Beta
2.13
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
14.68
www.rhythmtx.com